CorMedix is the specialty pharma behind DefenCath — the first FDA-approved catheter lock solution for preventing bloodstream infections in hemodialysis patients, approved November 2023. DefenCath generated $97.5M in Q1 2026, ≈77% of revenue. On July 1, 2026, its Medicare TDAPA reimbursement transitions to a permanent post-TDAPA add-on calculated by CMS, and the company has explicitly told investors that reimbursement to dialysis institutions will "significantly decline." Stock at $7.55, down from 52-week high $17.43.

What the filing says

Q1 2026 revenue $127.4M (+226% YoY). Operating income $63.7M. Net income $38.6M ($0.43 diluted). Operating cash flow $42.4M. Cash $178M; net cash ≈$28M after $150M convertible due 2030. DefenCath alone $97.5M (+149% YoY).

Management on TDAPA: reimbursement "will significantly decline, and as a result, CorMedix expects a corresponding reduction to its net pricing for DefenCath in the second half of 2026." Hedged recovery language: "the 2027 payment could increase meaningfully above the payment rate for the second half of 2026." No magnitude provided.

REZZAYO (rezafungin) hit Phase 3 in allogeneic HSCT prophylaxis April 27, 2026 — non-inferiority vs posaconazole + fluconazole. $143M IPR&D carried at Melinta acquisition close (Aug 2025). $20-25M milestone owed to Napp/Mundipharma on approval, plus tiered royalties.

$75M buyback authorized Feb 2026 with full knowledge of the cliff; $11.1M deployed Q1 at avg $6.97 — below current price. Three customers = 77% revenue. All CMOs European; April 2026 API tariff exposure unquantified. Material weakness from Melinta integration still open. Securities class action (2019-2022 period) in discovery; fact deadline Sept 25, 2026.

What the market thinks

Stock $7.55, market cap $600M, EV ≈$420M. Forward P/E 9.44x = consensus models ≈53% EPS compression vs Q1 annualized. Trailing P/E 3.48x. 21% short interest, 16 days to cover. Options inverted IV term structure (Aug 74% vs Jun 58%) — positioned for July 1 cliff. Sell-side 100% bullish, mean target $15.14 (+100% from spot).

Reverse-engineering the implied state distribution under max-stress assumptions (5x EBIT multiple, 25% op margin in distressed states, $40M REZZAYO NPV, $80M litigation reserve): roughly 5% mild / 25% base / 45% severe / 25% Korsuva-replay.

Where the gap is

Korsuva (Cara/CSL Vifor, cliff April 1, 2024) is the only fully-played-out ESRD-bundle TDAPA-to-post-TDAPA precedent. US revenue collapsed 92% in Year 1 ($26.5M → $2.1M). CMS post-TDAPA rate: $0.4601/treatment (CY2025), $0.2633 proposed (CY2026) — ≈98% off the TDAPA-era rate.

DefenCath has four structural mitigants Korsuva lacked: (1) clinical-protocol use for CRBSI prevention vs Korsuva's voluntary symptom-driven dosing; (2) TDAPA rate $2.37/treatment = 5x Korsuva's $0.46, producing a higher absolute floor under the same 65%-of-trailing-expenditure CMS methodology; (3) accelerating pre-cliff utilization (+149% YoY) vs Korsuva's decline; (4) life-threatening indication vs symptom relief.

Calibrated state distribution: 15% mild (25-40% revenue compression) / 40% base (50-65%) / 30% severe (75-85%) / 15% kors (90%+). Central case ≈55-60% compression; H2 2026 DefenCath ≈$35-50M/quarter (vs Q1 $97.5M).

Probability-weighted fair value under moderate stress (6x multiple, mixed margins, $75M REZZAYO NPV) ≈$11.75. Under max stress with calibrated distribution still ≈$9.08. Distribution-deviation edge from market-implied: ≈50pp across states.

Why the gap exists

Sell-side anchored to pre-cliff economics — $15 mean target implies s_mild base case. Buy-side internalized the cliff and applied Korsuva analog directly without adjusting for DefenCath's clinical-protocol and absolute-rate mitigants. The Korsuva precedent requires synthesizing Cara 10-K + CMS Federal Register methodology — uncommon for a $600M-cap, 7-analyst coverage name. Q4 2025 -80% earnings miss reset trust in management, layering credibility discount on top of the fundamental discount.

Risks (ranked by impact)

1. CMS post-TDAPA rate publishes below $0.80/treatment (likely Q4 2026 Federal Register). Confirms Korsuva-magnitude collapse.
2. DaVita / Fresenius walk-back on DefenCath protocol use post-cliff. Could surface in Q2 2026 calls (Aug).
3. Securities class action settles above $100M. Discovery deadline Sept 25, 2026; no reserve booked.
4. REZZAYO sNDA delayed past 2027 or receives CRL. Bull leg compresses.
5. April 2026 tariffs materialize in margins. European CMO concentration; 2-3 year onshoring window.
6. Material weakness not remediated by FY26 10-K. Restatement risk.

Catalysts

• July 1, 2026 — TDAPA cliff
• ~Aug 6, 2026 — Q2 2026 earnings (last full TDAPA quarter; possible squeeze)
• Sept 25, 2026 — Securities class fact discovery deadline
• Q4 2026 — CMS finalized FY2027 ESRD PPS rule
• ~Nov 5, 2026 — Q3 2026 earnings; first clean post-cliff quarter (the inflection)
• H2 2027 — REZZAYO sNDA PDUFA target

What would change our mind

• Insider Form 4 open-market sale before July 1 (no opens YTD)
• CMS draft rate < $0.80/treatment → Korsuva replay confirmed
• DaVita Q2 call walks back DefenCath protocol use → mitigant doesn't bind
• Q3 2026 DefenCath revenue < $30M → s_kors realizing
• Conversely: CMS rate > $1.20/treatment, Q3 DefenCath > $60M, KCAPA legislative motion → bull case confirmed

Cross-ticker: AKBA (Vafseo, cliff Dec 31, 2026) shares the same esrd-bundle-tdapa-cliff factor. DefenCath's July resolution is direct calibration data for AKBA before its own cliff hits.

Evidence